WWW - Posts tagged QDEL at BloggingStocks

QDEL posts

Analyst upgrades, downgrades and initiations: ABT, BA, CLWR, LLY, LTD, NFLX ...

Posted Dec 1st 2009 11:30AM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Netflix, Inc. (NFLX), Boeing Co (BA), Analyst Initiations

Analyst upgrades:

Stephens upgraded Quidel (QDEL) to equal weight from underweight on valuation following the recent pullback in shares. The firm keeps a $16 price target on the stock.
UBS upgraded Clearwire (CLWR) to neutral from sell, citing the company's funding, which increases opportunities. The firm raised its price target to $6 from $3.
Oppenheimer upgraded Mattson Technology (MTSN) to outperform from perform on expectations the company will benefit from a cyclical recovery in memory capex spending in 2010. The firm raised its target on shares to $4 from $3.
Eli Lilly (LLY) was upgraded to sell from conviction sell at Goldman.
Kinross Gold (KGC) was upgraded to overweight from neutral at JPMorgan.
Limited Brands (LTD) was upgraded to hold from sell at Soleil.

Continue reading Analyst upgrades, downgrades and initiations: ABT, BA, CLWR, LLY, LTD, NFLX ...

With Quidel, the focus is on the diagnosis

Posted Mar 24th 2008 5:26PM by Joseph Lazzaro (RSS feed)
Filed under: Stocks to Buy

The choppy/consolidating (or perhaps worse) market conditions sometimes give the impression that growth plays do not exist, but that is not the case, and one growth company worth a review is Quidel Corp. (Note: Quidel is only for investors who can tolerate high-risk.)

Quidel Corporation (Nasdaq: QDEL) develops, manufactures, and markets point-of-care, rapid diagnostic tests for the detection and management of a variety of medical conditions and illnesses. Its products are used to identify a pregnancy, and detect infectious diseases, autoimmune diseases, and osteoporosis, among other conditions.

Analysts like Quidel's flu testing market share, and solid positions in strep and pregnancy detection. Analysts expect 15-20% revenue growth in 2008, after a double-digit increase in 2007.

Continue reading With Quidel, the focus is on the diagnosis